Overview
- The companies announced on Wednesday that INTerpath-001, a Phase 3 trial of intismeran autogene plus pembrolizumab, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
- The randomized two-to-one study enrolled 1,137 patients with completely resected stage IIB–IV melanoma and reported no new safety signals compared with prior studies.
- Moderna and Merck have released only topline success and said they will present hazard ratios, confidence intervals, absolute effect sizes and additional safety data at an upcoming medical conference while overall survival is still being followed.
- Investors revalued Moderna and partners sharply after the announcement, more than doubling Moderna’s market value in days, while analysts warn the rally may outpace realistic sales forecasts because of narrow indications and high per-patient costs.
- The therapy is individualized: each patient’s tumor is sequenced, up to 34 neoantigens are selected and a bespoke mRNA dose is manufactured, which raises questions about manufacturing scale, likely price per patient and how well the approach will work in cancers with fewer mutations.